Dr. Moriarty is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
Mail Stop 3008
Kansas City, KS 66160Phone+1 913-588-6057Fax+1 913-588-4074
Summary
- Dr. Patrick Moriarty is a Professor of Medicine at the The University of Kansas Hospital. He received his medical degree from Sapienza University of Rome and has been in practice 26 years. He is Director of Clinical Pharmacology and the Atherosclerosis & Lipid-apheresis Center.
is a fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, National Lipid Association, and he was the 2014-2015 president of the International Society for Apheresis. He serves as a manuscript reviewer for multiple scientific journals and is the associate editor for the Journal of Clinical Apheresis and Clinical Lipidology.
He has published over 100 peer reviewed articles/chapters. His research activities include such topics as atherosclerosis, familial hypercholesterolemia, Lp(a), Lipoprotein-Apheresis, vascular Inflammation, dementia and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, dementia, and diabetes. Moreover, Dr. Moriarty is a member of the scientific advisory board for the FH Foundation. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipoprotein-Apheresis Center is the largest in North America for the treatment of Familial Hypercholesterolemia and elevated Lp(a).
Education & Training
- University of Kansas School of MedicineResidency, Internal Medicine, 1991 - 1994
- Sapienza University of RomeClass of 1991
- St. Michael's CollegeBA
Certifications & Licensure
- KS State Medical License 1994 - 2025
- MO State Medical License 2021 - 2025
- National Board of Physicians and Surgeons Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Who’s Who in Diabetes Treatment, Education and Research 2008
- Merck Young Investigator's Award 1998
- Join now to see all
Clinical Trials
- Treating Congestive Heart Failure Using a Device to Remove Cholesterol Start of enrollment: 2007 Jul 01
- (H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol Start of enrollment: 2007 Aug 01
- Alternative Options to Minimize Niacin-Induced Flushing Start of enrollment: 2009 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Bempedoic Acid Falls in Line.Maya S Safarova, Patrick M Moriarty, Iftikhar J Kullo, Christie M Ballantyne, Eugenia Gianos
Journal of the American College of Cardiology. 2024-07-09 - 11 citationsEvinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.Albert Wiegman, Susanne Greber-Platzer, Shazia Ali, M Doortje Reijman, Eliot A Brinton
Circulation. 2024-01-30 - 3 citationsConsiderations for routinely testing for high lipoprotein(a).Nick S Nurmohamed, Patrick M Moriarty, Erik Sg Stroes
Current Opinion in Lipidology. 2023-08-01
Journal Articles
- Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Sever...Raul D Santos, Samuel S Gidding, Robert A Hegele, Marina A Cuchel, Philip J Barter, Gerald F Watts, Seth J Baum, Alberico L Catapano, M John Chapman, Joep C Defesche, ..., Lancet Diabetes-Endocrinol, 1/1/2016
- JCL Roundtable: PCSK9 Inhibitors in Clinical PracticeBrown WV, Moriarty PM, McKenney JM, Journal of Clinical Lipidology, 1/1/2016
- JCL Roundtable: Should We Treat Elevations in Lp(a)?Brown WV, Moriarty PM, Remaley AT, Tsimikas S, Journal of Clinical Lipidology, 1/1/2016
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Impact Of Lipoprotein Apheresis on Serum Myeloperoxidase Levels in Patients with Familial HypercholesterolemiaSehar N, Moriarty, PM, European Atherosclerosis Society, Glasgow, Scotland, 1/1/2015
- Long Term Follow up of Bi-Weekly Lipoprotein Apheresis in A patient with Elevated Lipoprotein-(a) Shows Regression in Carotid Intima-Media ThicknessAbeer Anabtawi, Priyanka Patel, Lisa Deuschele, Patrick Moriarty, National Lipid Association, Chicago, Illinois, 1/1/2015
- Resolution of recurrent postoperative pericarditis after lipid apheresis: a case reportMoriarty PM, Heckerson N, Journal of Clinical Lipidology, 1/1/2012
- Join now to see all
Lectures
- Diagnosis and treatment of abnormal cholesterolemia in the diabetic patient including the metabolic syndrome patientKU Med - 1/1/2005
- Diabetic Lipid Management: How low should we go?Kansas City, MO - 1/1/2005
- Atherosclerosis and its association with hemorheologySt. Luke’s Hospital, Kansas City, MO - 1/1/2005
- Join now to see all
Other
- Expert Roundtable: Familial HypercholesterolemiaUnderberg James, Brinton, Eliot, McGowan, Mary, Moriarty PM, The Medical Roundtable: Cardiovascular Edition
1/1/2012 - Lipoprotein-Associate Phospholipase A2: Effects of Low Density Lipoprotein ApheresisMoriarty PM, ather.org
1/1/2005 - Patient Presents to the Atherosclerosis and Lipoprotein Apheresis Clinic Unable to Reach LDL-C Goal Despite Lipid-Modifying AgentsMoriarty PM, http://www.acc.org
http://education.acc.org/Lifelong-Learning-and-MOC/Certified-Learning/Case-Vignettes/2015/Prevention/Prev_FH_HoFH_Moriarty.aspx
1/26/2015 - Join now to see all
Press Mentions
- Fundraiser Planned for Child Who Suffered StrokesJuly 25th, 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: